

## ASX ANNOUNCEMENT

19 January 2023

# Results of Share Purchase Plan



Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") wishes to announce the results of its Share Purchase Plan ("**SPP**") which closed on 16 January 2023.

LGP advises the Company received \$897,500 in applications under the SPP for 4,487,500 fully paid ordinary shares at an issue price of \$0.20 per share ("**SPP Shares**"). Each share subscribed for under the SPP will also receive a free-attaching option with an exercise price of \$0.25 ("**SPP Options**").

According to the SPP timetable, the SPP Shares and SPP Options will be issued today, 19 January 2023, with the SPP Shares to be quoted on 20 January 2023.

LGP thanks participating shareholders for their ongoing support.

**ENDS**  
**BY ORDER OF THE BOARD**

A handwritten signature in black ink, appearing to be "Alistair Warren".

**Alistair Warren**  
Company Secretary



For further information please contact:

**Alistair Warren**  
**Company Secretary**

Little Green Pharma  
E: [a.warren@lgp.global](mailto:a.warren@lgp.global)  
T: +618 6280 0050

**Fleta Solomon**  
**Chief Executive Officer**

Little Green Pharma  
E: [f.solomon@lgp.global](mailto:f.solomon@lgp.global)  
T: +618 6280 0050

## About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m<sup>2</sup> cultivation and 4,000m<sup>2</sup> GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)